What is the half-life of nortriptyline (tricyclic antidepressant) in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Nortriptyline

Pharmacokinetic Parameters

The elimination half-life of nortriptyline in adults ranges from 14 to 51 hours under normal therapeutic conditions, with most patients experiencing a half-life of approximately 30-36 hours. 1

Key Clinical Considerations

Standard Therapeutic Dosing

  • Under normal therapeutic conditions with doses of 10-25 mg daily, nortriptyline demonstrates a half-life of approximately 30-36 hours in most patients 2
  • This relatively long half-life allows for once-daily or twice-daily dosing regimens 1
  • Steady-state plasma concentrations are typically achieved within approximately 5-7 days (approximately 5 half-lives) 1

Factors Affecting Half-Life

Age and renal function significantly impact nortriptyline elimination, as metabolite clearance is ultimately dependent on renal elimination 3. Elderly patients may experience:

  • Accumulation of hydroxy-metabolites due to reduced renal function 3
  • Increased risk of cardiovascular and other toxicities from metabolite accumulation 3

Toxic Ingestions and Overdose

In massive overdose situations, nortriptyline pharmacokinetics become highly unpredictable and the half-life can be dramatically prolonged. 4

  • A documented case demonstrated an elimination half-life of 184 hours (approximately 7.7 days) following a massive overdose of 2500 mg 4
  • This represents more than a 3-fold increase compared to therapeutic dosing 4
  • The prolonged half-life in overdose is attributed to:
    • Delayed absorption 4
    • Enterohepatic recirculation 4
    • Large volume of distribution 4
    • Saturable (capacity-limited) metabolism 4, 2

Capacity-Limited Metabolism

Nortriptyline exhibits dose-dependent (nonlinear) pharmacokinetics in some patients, even at therapeutic doses. 2

  • One case report documented half-lives increasing from 30.4 hours at 10 mg every other day to 64 hours at 25 mg daily 2
  • This capacity-limited metabolism means that small dose increases can result in disproportionately large increases in plasma concentrations 2

Drug Interactions

Drug interactions can dramatically prolong nortriptyline half-life through cytochrome P450 inhibition. 5

  • Fluoxetine and its long-acting metabolite norfluoxetine can cause severe, slowly reversible inhibition of nortriptyline metabolism 5
  • One case documented an amitriptyline (parent compound of nortriptyline) half-life of approximately 120 hours when combined with fluoxetine, even in a patient with normal CYP2D6 function 5

Clinical Implications for Discontinuation

When discontinuing nortriptyline, a gradual taper over 10-14 days is recommended to minimize withdrawal symptoms, similar to other antidepressants with moderate half-lives 6

Important Caveats

  • Do not rely on standard pharmacokinetic parameters to guide clinical decisions in overdose situations 4
  • In toxic ingestions, urine tricyclic antidepressant screens and QRS duration provide more reliable guidance than calculated half-lives 4
  • Therapeutic drug monitoring should occur at steady state (approximately 1 week after stable dosing) with samples collected 12-16 hours after the last dose 7
  • The therapeutic window for nortriptyline is narrow (50-150 ng/mL), making monitoring particularly important 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Nortriptyline capacity-limited metabolism: a case report.

Journal of clinical psychopharmacology, 1984

Guideline

Paroxetine Discontinuation Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Paroxetine Pharmacokinetics and Clinical Implications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.